Varex Imaging (VREX)
Market Price (12/4/2025): $11.65 | Market Cap: $483.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
Varex Imaging (VREX)
Market Price (12/4/2025): $11.65Market Cap: $483.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% | Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -116% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 66% |
| Attractive yieldFCF Yield is 10% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.2%, Rev Chg QQuarterly Revenue Change % is -2.9% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% |
| Attractive yieldFCF Yield is 10% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -116% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 66% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.2%, Rev Chg QQuarterly Revenue Change % is -2.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% |
Valuation, Metrics & Events
VREX Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are key points highlighting potential reasons for Varex Imaging (VREX) stock moving by approximately -0.8% during the period from August 31, 2025, to December 4, 2025:
1. Weaker First Quarter Fiscal Year 2026 Guidance: Despite reporting strong fourth-quarter and full fiscal year 2025 results, Varex Imaging provided a more cautious outlook for the first quarter of fiscal year 2026. The company projected revenues between $200 million and $215 million and non-GAAP net earnings per diluted share between $0.05 and $0.25. This guidance is lower than the Q4 FY25 performance and could have tempered investor enthusiasm, contributing to a slight stock decline over the period.
2. Decreased Cash Reserves: Varex Imaging's cash, cash equivalents, and marketable securities decreased to $155 million at the end of fiscal year 2025, down from $213 million at the end of fiscal year 2024. This change was primarily attributed to the use of cash to pay down outstanding convertible notes. While debt reduction is often positive, a notable decrease in cash reserves can sometimes raise liquidity concerns among investors, especially if other market uncertainties exist.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VREX Return | -44% | 89% | -36% | 1% | -29% | -22% | -62% |
| Peers Return | 9% | 21% | -13% | -12% | 4% | 12% | 19% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| VREX Win Rate | 42% | 75% | 33% | 50% | 33% | 30% | |
| Peers Win Rate | 27% | 31% | 19% | 21% | 23% | 65% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| VREX Max Drawdown | -65% | 0% | -39% | -15% | -50% | -53% | |
| Peers Max Drawdown | -23% | -4% | -19% | -17% | -8% | -9% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HOLX, ANGO, AVRT, BLLN, BNBX. See VREX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | VREX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -46.7% | -25.4% |
| % Gain to Breakeven | 87.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -66.8% | -33.9% |
| % Gain to Breakeven | 201.1% | 51.3% |
| Time to Breakeven | 478 days | 148 days |
| 2018 Correction | ||
| % Loss | -49.7% | -19.8% |
| % Gain to Breakeven | 98.8% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to HOLX, ANGO, AVRT, BLLN, BNBX
In The Past
Varex Imaging's stock fell -46.7% during the 2022 Inflation Shock from a high on 12/29/2021. A -46.7% loss requires a 87.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to VREX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Varex Imaging
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.49 |
| Mkt Cap | 0.6 |
| Rev LTM | 561 |
| Op Inc LTM | 22 |
| FCF LTM | 12 |
| FCF 3Y Avg | 17 |
| CFO LTM | 26 |
| CFO 3Y Avg | 30 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.2% |
| Rev Chg 3Y Avg | -5.1% |
| Rev Chg Q | 5.5% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | -0.4% |
| Op Mgn 3Y Avg | -0.7% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 2.3% |
| CFO/Rev 3Y Avg | 2.4% |
| FCF/Rev LTM | 0.2% |
| FCF/Rev 3Y Avg | 0.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 1.5 |
| P/EBIT | -9.3 |
| P/E | -2.7 |
| P/CFO | 6.0 |
| Total Yield | -7.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 5.4% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.8% |
| 3M Rtn | 13.2% |
| 6M Rtn | 23.1% |
| 12M Rtn | -3.2% |
| 3Y Rtn | -1.9% |
| 1M Excs Rtn | -1.7% |
| 3M Excs Rtn | 7.6% |
| 6M Excs Rtn | 8.4% |
| 12M Excs Rtn | -19.2% |
| 3Y Excs Rtn | -71.2% |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 6302025 | 8072025 | 10-Q 7/4/2025 |
| 3312025 | 5082025 | 10-Q 4/4/2025 |
| 12312024 | 2062025 | 10-Q 1/3/2025 |
| 9302024 | 11192024 | 10-K 9/30/2024 |
| 6302024 | 8012024 | 10-Q 6/28/2024 |
| 3312024 | 5022024 | 10-Q 3/29/2024 |
| 12312023 | 2062024 | 10-Q 12/29/2023 |
| 9302023 | 11162023 | 10-K 9/30/2023 |
| 6302023 | 8012023 | 10-Q 6/30/2023 |
| 3312023 | 5022023 | 10-Q 3/31/2023 |
| 12312022 | 1312023 | 10-Q 12/30/2022 |
| 9302022 | 11182022 | 10-K 9/30/2022 |
| 6302022 | 8032022 | 10-Q 7/1/2022 |
| 3312022 | 5042022 | 10-Q 4/1/2022 |
| 12312021 | 2082022 | 10-Q 12/31/2021 |
| 9302021 | 11192021 | 10-K 9/30/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |